Gluamet (Metformin Hydrochloride, Vildagliptin)

GluaMet is indicated for the treatment of adults with type 2 diabetes mellitus when diet, exercise, and monotherapy with either metformin or a DPP‑4 inhibitor do not provide adequate glycemic control.

• Adjunct to lifestyle modification for improved fasting plasma glucose.
• Combined therapy to lower HbA1c in patients inadequately controlled on metformin alone.
• Use in patients who require both hepatic glucose reduction and enhanced incretin response.
• Suitable for individuals with renal function within metformin prescribing limits.
• Can be part of a step‑wise treatment algorithm for type 2 diabetes.

The safety profile of GluaMet reflects the combined effects of metformin and vildagliptin, with adverse events ranging from mild gastrointestinal symptoms to rare but serious metabolic disturbances.

Common

• Nausea, vomiting, or abdominal discomfort.
• Diarrhea or loose stools.
• Upper respiratory tract infection symptoms.
• Mild headache or dizziness.
• Metallic taste in the mouth.
• Indigestion or heartburn.
• Transient loss of appetite.
• Mild skin rash.

Serious

• Lactic acidosis, a rare but life‑threatening condition.
• Severe hypoglycemia, especially when combined with insulin or sulfonylureas.
• Pancreatitis presenting with abdominal pain and elevated enzymes.
• Severe allergic reactions such as rash, swelling, or anaphylaxis.
• Renal impairment leading to accumulation of metformin.

When prescribing GluaMet, clinicians should consider patient-specific factors and monitor for conditions that may increase the risk of adverse events or reduce therapeutic effectiveness.

• Assess renal function before initiating therapy and periodically thereafter.
• Avoid use in patients with a history of lactic acidosis.
• Use caution in individuals with hepatic impairment.
• Do not initiate in patients with active pancreatitis.
• Adjust dose in elderly patients or those with reduced kidney function.
• Discontinue if severe hypoglycemia or signs of lactic acidosis occur.
• Monitor blood glucose regularly to detect hypo‑ or hyperglycemia.

GluaMet may interact with other medicines, affecting glucose control or increasing the risk of side effects; reviewing a patient’s medication list is essential before starting therapy.

Avoid

• Concurrent use with other biguanides or high‑dose metformin.
• Combination with insulin or sulfonylureas without dose adjustment.
• Co‑administration with iodinated contrast agents in patients with renal impairment.
• Use with strong CYP2C9 inhibitors that may affect vildagliptin metabolism.
• Avoid use with alcohol excess, which can increase risk of lactic acidosis.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms.
• Diuretics can alter electrolyte balance, influencing renal clearance.
• Corticosteroids may raise blood glucose, requiring closer monitoring.
• ACE inhibitors may affect renal function; monitor creatinine when combined.